NASDAQ$LQDA
Liquidia Corporation · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Liquidia reported full year 2022 financial results and provided a corporate update.
Liquidia Corporation reported its full year 2022 financial results, with a focus on advancements in their legal and patent landscape, progress towards potential YUTREPIA launch, and strategic financial initiatives. The company highlighted key employee hires, clarified legal pathways with favorable patent rulings, and increased commitment to the Treprostinil Injection market through new collaborations. They fortified their financial position through strategic financing, ensuring they are well-positioned for the potential launch of YUTREPIA.
- Hired key employees in preparation for potential YUTREPIA launch.
- Demonstrated favorable legal outcomes regarding key patents related to YUTREPIA.
- Increased long-term commitment to Treprostinil Injection market through collaborations.
- Fortified financial position through strategic financing initiatives.
Headline financials
Revenue & EPS history
Liquidia · Revenue · Quarterly
$5.36M
Revenue by segment
Liquidia · $3.7M total across 1 segment · Q3 2023
- Promotion Agreement$3.7M+15.6%100.0%
Forward guidance
Liquidia is focused on the potential commercialization of YUTREPIA, navigating legal challenges, and expanding access to Treprostinil Injection.
Tailwinds
- Potential FDA approval of YUTREPIA for PAH and PH-ILD.
- Ongoing open-label extension study demonstrating YUTREPIA's dosing flexibility and durability.
- Strategic partnerships to advance a new subcutaneous infusion pump for Treprostinil Injection.
- Favorable legal rulings clarifying the path to potential YUTREPIA approval.
- Extended promotion agreement for Treprostinil Injection until December 31, 2032.
Headwinds
- Ongoing appeals in patent litigation could delay YUTREPIA's approval.
- Uncertainty regarding the timing of legal resolution.
- Dependence on the existing CADD-MS 3 system for subcutaneous delivery of Treprostinil Injection.
- Potential for increased competition in the PAH treatment market.
- Risks associated with the development and commercialization of new pharmaceutical products.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
+3.4%
Avg return
Earnings day
+5.4%
Avg return
5 days after
+1.7%
Avg return
30 days after
60%
18 / 30 earnings
Positive
+31.8%
Q2 2022
Best reaction
-13.3%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +25.4% | +34.5% | — | |
| Q4 2025 | +0.4% | +12.9% | +9.6% | |
| Q3 2025 | +8.8% | +7.1% | +38.5% | |
| Q1 2025 | -1.0% | +3.0% | +16.8% | |
| Q4 2024 | +1.2% | +6.2% | -6.9% | |
| Q3 2024 | -5.6% | -7.6% | +2.7% | |
| Q2 2024 | +2.9% | +10.4% | -17.7% | |
| Q1 2024 | -0.8% | +5.4% | +10.4% | |
| Q4 2023 | +9.6% | +11.3% | -0.2% | |
| Q3 2023 | -1.0% | -4.4% | +9.8% | |
| Q2 2023 | -6.3% | -8.9% | -7.5% | |
| Q1 2023 | +5.0% | +7.8% | +26.1% | |
| Q4 2022 | +13.5% | +13.2% | +6.3% | |
| Q3 2022 | +0.8% | -0.4% | +14.6% | |
| Q2 2022 | +31.8% | +34.5% | +9.9% | |
| Q1 2022 | +7.7% | +21.9% | -17.0% | |
| Q4 2021 | +11.2% | +9.7% | -17.8% | |
| Q3 2021 | +9.9% | +9.7% | +3.1% | |
| Q2 2021 | -0.8% | +11.8% | +16.4% | |
| Q1 2021 | -0.7% | +0.0% | -0.7% | |
| Q4 2020 | -7.4% | -6.6% | +2.2% | |
| Q3 2020 | +0.7% | -12.7% | -36.9% | |
| Q2 2020 | -13.3% | -8.5% | -23.3% | |
| Q1 2020 | +8.0% | +8.7% | +13.4% | |
| Q4 2019 | -1.5% | +1.7% | +54.5% | |
| Q3 2019 | +5.2% | +0.6% | +6.4% | |
| Q2 2019 | +6.4% | -0.7% | -40.6% | |
| Q1 2019 | -3.0% | -0.4% | +2.6% | |
| Q4 2018 | +3.0% | +3.1% | -43.8% | |
| Q3 2018 | -9.2% | -1.3% | +19.4% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro